149 related articles for article (PubMed ID: 2582610)
1. Brainstem serotonergic hyperinnervation modifies behavioral supersensitivity to 5-hydroxytryptophan in the rat.
Pranzatelli MR; Huang YY; Dollison AM; Stanley M
Brain Res Dev Brain Res; 1989 Nov; 50(1):89-99. PubMed ID: 2582610
[TBL] [Abstract][Full Text] [Related]
2. Intracisternal 5,7-dihydroxytryptamine lesions in neonatal and adult rats: comparison of response to 5-hydroxytryptophan.
Pranzatelli MR; Dollison AM; Hlibczuk V
Dev Neurosci; 1989; 11(3):205-11. PubMed ID: 2788568
[TBL] [Abstract][Full Text] [Related]
3. The functional significance of neonatal 5,7-dihydroxytryptamine lesions in the rat: response to selective 5-HT1A and 5-HT2,1C agonists.
Pranzatelli MR; Dollison AM; Huang YY
Brain Res Bull; 1990 Jun; 24(6):747-53. PubMed ID: 2142615
[TBL] [Abstract][Full Text] [Related]
4. Serotonin-lesion myoclonic syndromes. II. Analysis of individual syndrome elements, locomotor activity and behavioral correlations.
Pranzatelli MR; Snodgrass SR
Brain Res; 1986 Jan; 364(1):67-76. PubMed ID: 3484993
[TBL] [Abstract][Full Text] [Related]
5. The guinea pig myoclonic model: behavioral supersensitivity to 5-hydroxytryptophan induced by intracisternal 5,7-dihydroxytryptamine.
Pranzatelli MR; Snodgrass SR
Eur J Pharmacol; 1987 Nov; 143(2):237-42. PubMed ID: 3500866
[TBL] [Abstract][Full Text] [Related]
6. Enhanced selective 5-HT depletions in the DHT rat model: denervation supersensitivity and recovery of function.
Pranzatelli MR; Snodgrass SR
Psychopharmacology (Berl); 1986; 89(4):449-55. PubMed ID: 3092275
[TBL] [Abstract][Full Text] [Related]
7. Behavioral and prolactin responses to 5-hydroxytryptophan in rats treated during development with 5,7-dihydroxytryptamine.
Breese GR; Vogel RA; Kuhn CM; Mailman RB; Mueller RA; Schanberg SM
Brain Res; 1978 Oct; 155(2):263-75. PubMed ID: 308387
[TBL] [Abstract][Full Text] [Related]
8. Chronic ACTH treatment: influence on 5-HT2 receptors and behavioral supersensitivity induced by 5,7-dihydroxytryptamine lesions.
Pranzatelli MR; Eng B
Peptides; 1989; 10(1):5-8. PubMed ID: 2546129
[TBL] [Abstract][Full Text] [Related]
9. Regional central serotonin-2 receptor binding and phosphoinositide turnover in rats with 5,7-dihydroxytryptamine lesions.
Butler PD; Pranzatelli MR; Barkai AI
Brain Res Bull; 1990 Jan; 24(1):125-9. PubMed ID: 2155684
[TBL] [Abstract][Full Text] [Related]
10. Supersensitivity to L-5-hydroxytryptophan after 5,7-dihydroxytryptamine injections in desmethylimipramine- and nomifensine-pretreated rats: behavioral evidence for postsynaptic supersensitivity.
Ortmann R; Martin S; Waldmeier PC
Psychopharmacology (Berl); 1981; 74(2):109-14. PubMed ID: 6115443
[TBL] [Abstract][Full Text] [Related]
11. Effect of 5,7-dihydroxytryptamine on serotonergic control of prolactin secretion and behavior in rats.
Kuhn CM; Vogel RA; Mailman RB; Mueller RA; Schanberg SM; Breese GR
Psychopharmacology (Berl); 1981; 73(2):188-93. PubMed ID: 6785814
[TBL] [Abstract][Full Text] [Related]
12. Serotonin-lesion myoclonic syndromes. I. Neurochemical profile and S-1 receptor binding.
Pranzatelli MR; Rubin G; Snodgrass SR
Brain Res; 1986 Jan; 364(1):57-66. PubMed ID: 3484992
[TBL] [Abstract][Full Text] [Related]
13. The comparative pharmacology of the behavioral syndromes induced by TRH and by 5-HT in the rat.
Pranzatelli MR
Gen Pharmacol; 1988; 19(2):205-11. PubMed ID: 2895033
[TBL] [Abstract][Full Text] [Related]
14. 5-HT depletion with 5,7-DHT, PCA and PCPA in mice: differential effects on the sensitivity to 5-MeODMT, 8-OH-DPAT and 5-HTP as measured by two nociceptive tests.
Eide PK; Hole K; Berge OG; Broch OJ
Brain Res; 1988 Feb; 440(1):42-52. PubMed ID: 2965956
[TBL] [Abstract][Full Text] [Related]
15. 1-5-Hydroxytryptophan-induced flat body posture in the rat: antagonism by ritanserin and potentiation after 5,7-dihydroxytryptamine.
Colpaert FC; Koek W; Lategan A
Eur J Pharmacol; 1989 Oct; 169(1):175-8. PubMed ID: 2513211
[TBL] [Abstract][Full Text] [Related]
16. Potentiation in phencyclidine-induced serotonin-mediated behaviors after intracerebroventricular administration of 5,7-dihydroxytryptamine in rats.
Nabeshima T; Yamaguchi K; Ishikawa K; Furukawa H; Kameyama T
J Pharmacol Exp Ther; 1987 Dec; 243(3):1139-46. PubMed ID: 2826756
[TBL] [Abstract][Full Text] [Related]
17. Intracerebroventricular administration of 5,7-dihydroxytryptamine to mice increases both head-twitch response and the number of cortical 5-HT2 receptors.
Heal DJ; Philpot J; Molyneux SG; Metz A
Neuropharmacology; 1985 Dec; 24(12):1201-5. PubMed ID: 4094656
[TBL] [Abstract][Full Text] [Related]
18. Biochemical and behavioral alterations in developing rats treated with 5,7-dihydroxytryptamine.
Breese GR; Vogel RA; Mueller RA
J Pharmacol Exp Ther; 1978 Jun; 205(3):587-95. PubMed ID: 307057
[TBL] [Abstract][Full Text] [Related]
19. Effects of 5,7-dihydroxytryptamine on serotonin1 and serotonin2 receptors throughout the rat central nervous system using quantitative autoradiography.
Fischette CT; Nock B; Renner K
Brain Res; 1987 Sep; 421(1-2):263-79. PubMed ID: 3690273
[TBL] [Abstract][Full Text] [Related]
20. Increased sensitivity to intracerebroventricular infusion of serotonin and deaminated indoles after lesioning rat with dihydroxytryptamine.
Warbritton JD; Stewart RM; Baldessarini RJ
Brain Res; 1980 Feb; 183(2):355-66. PubMed ID: 6153283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
